Lin Kehao, Qin Ze, Qu Chuanjun, Chen Xiaoyu, Jiang Qingling, Li Minjing, Zheng Qiusheng, Li Defang
Yantai Key Laboratory of Pharmacology of Traditional Chinese Medicine in Tumor Metabolism, School of Integrated Traditional Chinese and Western Medicine, Binzhou Medical University, Yantai, Shandong 264003, P.R. China.
Department of Anesthesia, The Fourth Hospital of Shijiazhuang, Shijiazhuang, Hebei 050011, P.R. China.
Oncol Lett. 2021 May;21(5):426. doi: 10.3892/ol.2021.12687. Epub 2021 Mar 29.
Doxorubicin (DOX) is currently the preferred chemotherapeutic agent for breast cancer, and hydroxyl safflower yellow B (HSYB) has a tumor growth-inhibiting activity. The present study aimed to investigate the effects of HSYB combined with DOX on the proliferation of human breast cancer MCF-7 cells and explore the underlying mechanism. MTT and cell colony formation assays revealed that the proliferation rate of MCF-7 cells was signifiscantly decreased after HSYB and DOX treatment. Combined HSYB and DOX treatment significantly decreased the expression levels of BCL-2 in MCF-7 cells, while the expression levels of apoptosis-associated proteins, including cleaved caspase-9, BAX and cleaved caspase-3, were markedly increased. Furthermore, flow cytometry and western blot analysis demonstrated that combined HSYB and DOX treatment stimulated an increase in intracellular reactive oxygen species and promoted the release of cytochrome , leading to apoptosis. The current data suggested that the combination of HSYB and DOX may have marked antitumor activity.
阿霉素（DOX）是目前乳腺癌的首选化疗药物，而羟基红花黄色素B（HSYB）具有肿瘤生长抑制活性。本研究旨在探讨HSYB联合DOX对人乳腺癌MCF-7细胞增殖的影响，并探究其潜在机制。MTT和细胞集落形成试验表明，HSYB和DOX处理后MCF-7细胞的增殖率显著降低。HSYB与DOX联合处理显著降低了MCF-7细胞中BCL-2的表达水平，而凋亡相关蛋白（包括裂解的caspase-9、BAX和裂解的caspase-3）的表达水平则明显升高。此外，流式细胞术和蛋白质印迹分析表明，HSYB与DOX联合处理可刺激细胞内活性氧的增加，并促进细胞色素的释放，从而导致细胞凋亡。目前的数据表明，HSYB与DOX联合使用可能具有显著的抗肿瘤活性。
